Centessa Pharmaceuticals’ (CNTA) Buy Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research report sent to investors on Monday morning,Benzinga reports.

Separately, TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Stock Up 4.3 %

CNTA stock opened at $18.00 on Monday. The firm has a market cap of $2.37 billion, a PE ratio of -11.76 and a beta of 1.53. Centessa Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.09. The company has a fifty day simple moving average of $16.80 and a 200 day simple moving average of $15.56. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Sell-side analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the sale, the insider now directly owns 54,322 shares of the company’s stock, valued at $1,033,747.66. This represents a 35.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Tia L. Bush sold 11,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now owns 121,503 shares in the company, valued at approximately $2,048,540.58. The trade was a 8.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 452,652 shares of company stock valued at $7,800,532 in the last 90 days. 11.59% of the stock is currently owned by insiders.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of CNTA. Janus Henderson Group PLC acquired a new stake in Centessa Pharmaceuticals during the third quarter worth $20,698,000. Franklin Resources Inc. lifted its holdings in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after acquiring an additional 1,145,823 shares during the period. Point72 Asset Management L.P. boosted its position in shares of Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after acquiring an additional 953,659 shares in the last quarter. Baker BROS. Advisors LP increased its stake in Centessa Pharmaceuticals by 123.4% in the third quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company’s stock valued at $19,623,000 after acquiring an additional 677,966 shares during the period. Finally, Ally Bridge Group NY LLC acquired a new position in Centessa Pharmaceuticals in the third quarter worth about $4,951,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.